| Filed | Form | Items | Signal | Score | Summary | Link |
|---|---|---|---|---|---|---|
| 2026-08-21 17:12 | 8-K | ["1.01", "9.01"] | material agreement | 0.15 | Asset transfer agreement for Apitox rights; no M&A transaction or acquisition signal indicated. | SEC · detail |
| 2026-08-06 17:25 | 8-K | ["8.01", "9.01"] | officer change | 0.15 | Appointment of Chief Scientific Officer for internal program leadership; no M&A indicators. | SEC · detail |
| 2026-07-13 16:30 | 8-K | ["8.01", "9.01"] | other | 0.05 | Reverse stock split announcement; no M&A signals present. | SEC · detail |
| 2026-05-05 12:30 | 8-K | ["5.02"] | officer change | 0.15 | Appointment of Co-CEO with real estate/urban development background; unrelated to pharma operations, no M&A signal. | SEC · detail |
| 2026-05-04 06:15 | 8-K | ["1.01"] | material agreement | 0.15 | Settlement agreement resolving disputes from prior merger; no active M&A transaction indicated. | SEC · detail |